Merck Strikes $838M Antibody Discovery Deal with Infinimmune as Pharma Ramps Up AI-Driven Drug Research
Merck has entered an R&D collaboration worth up to $838 million with Infinimmune, a startup specializing in discovering immune cell-directed antibodies for multiple therapeutic targets.
The Deal
- Partner: Infinimmune (antibody discovery startup)
- Maximum value: $838 million
- Structure: R&D collaboration with milestone payments
- Focus: Immune cell-directed antibodies for multiple targets
About Infinimmune
Infinimmune is pioneering a new approach to antibody drug discovery that focuses on directing the immune system's own antibody-producing cells rather than traditional in vitro screening methods. This approach could yield antibodies with superior properties:
- Better tissue penetration
- More favorable safety profiles
- Enhanced efficacy through natural immune system optimization
Why It Matters
The $838M headline value reflects the enormous potential — and cost — of antibody drug development. Monoclonal antibodies represent one of the most successful drug classes in history, with global sales exceeding $200 billion annually.
This deal is part of a broader trend of major pharma companies partnering with innovative biotech startups to access novel drug discovery platforms, particularly as AI and computational biology transform the field.
Context: Big Pharma's Antibody Push
Major antibody-focused deals in 2026:
| Company | Deal | Value |
|---|---|---|
| Merck | Infinimmune collaboration | Up to $838M |
| Biogen | Apellis acquisition | $5.6B |
| Eli Lilly | Centessa acquisition | $6.3B |
| Blackstone | Life Sciences Fund | $6.3B |